JP2008508279A - 腎疾患を治療するためのビタミンｄの使用 - Google Patents

腎疾患を治療するためのビタミンｄの使用 Download PDF

Info

Publication number
JP2008508279A
JP2008508279A JP2007523596A JP2007523596A JP2008508279A JP 2008508279 A JP2008508279 A JP 2008508279A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2008508279 A JP2008508279 A JP 2008508279A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
vitamin
composition according
dosage form
paricalcitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007523596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508279A5 (enExample
Inventor
メルニツク，ジヨエル
テン，チン
ウイリアムズ，ローラ
デルガド−ハーレラ，レテイツイア
チユイ，ピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/901,660 external-priority patent/US20050148557A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2008508279A publication Critical patent/JP2008508279A/ja
Publication of JP2008508279A5 publication Critical patent/JP2008508279A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007523596A 2004-07-28 2005-07-08 腎疾患を治療するためのビタミンｄの使用 Withdrawn JP2008508279A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/901,660 US20050148557A1 (en) 2003-07-29 2004-07-28 Use of Vitamin Ds to treat kidney disease
US10/974,243 US20050124591A1 (en) 2003-07-29 2004-10-27 Use of vitamin Ds to treat kidney disease
PCT/US2005/024446 WO2006019659A1 (en) 2004-07-28 2005-07-08 Use of vitamin ds to treat kidney disease

Publications (2)

Publication Number Publication Date
JP2008508279A true JP2008508279A (ja) 2008-03-21
JP2008508279A5 JP2008508279A5 (enExample) 2008-10-02

Family

ID=34982541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007523596A Withdrawn JP2008508279A (ja) 2004-07-28 2005-07-08 腎疾患を治療するためのビタミンｄの使用

Country Status (5)

Country Link
US (1) US20050124591A1 (enExample)
EP (1) EP1786407A1 (enExample)
JP (1) JP2008508279A (enExample)
CA (1) CA2575155A1 (enExample)
WO (1) WO2006019659A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536301A (ja) * 2012-10-09 2015-12-21 レグルス セラピューティクス インコーポレイテッド アルポート症候群の処置方法
JP2016523890A (ja) * 2013-06-27 2016-08-12 ヴィルバク 進行性腎疾患の治療のための組成物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001969A1 (en) * 2005-06-27 2007-01-04 The General Hospital Corporation Vitamin d deficiency and dialysis
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
EP2129382A4 (en) * 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR HEART MUSCLE PREVENTION
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) * 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2148685A4 (en) * 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
CA2703994C (en) * 2007-11-06 2017-05-23 The Salk Institute For Biological Studies Use of vitamin d receptor agonists and precursors to treat fibrosis
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
JP5908402B2 (ja) 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腎疾患の予防方法およびその症状を処置する方法
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
MX393138B (es) 2011-04-25 2025-03-24 Sanofi Sa Compuestos de microarn y metodos para modular la actividad de mir-21.
MY173600A (en) 2012-04-25 2020-02-08 Sanofi Sa Microrna compounds and methods for modulating mir-21 activity
MY172886A (en) 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014257051A1 (en) 2013-04-24 2015-11-19 Salk Institute For Biological Studies Vitamin D receptor/SMAD genomic circuit gates fibrotic response
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
ES2968898T3 (es) * 2019-06-06 2024-05-14 Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz Método in vitro para detectar enfermedad renal
KR102941060B1 (ko) * 2023-07-10 2026-03-18 고려대학교 산학협력단 미세먼지에 의한 신장 질환의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747008B1 (en) * 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
FR2825087B1 (fr) * 2001-05-22 2005-01-14 Galderma Res & Dev Analogues de la vitamine d

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536301A (ja) * 2012-10-09 2015-12-21 レグルス セラピューティクス インコーポレイテッド アルポート症候群の処置方法
JP2016523890A (ja) * 2013-06-27 2016-08-12 ヴィルバク 進行性腎疾患の治療のための組成物

Also Published As

Publication number Publication date
CA2575155A1 (en) 2006-02-23
EP1786407A1 (en) 2007-05-23
WO2006019659A1 (en) 2006-02-23
US20050124591A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
US20050124591A1 (en) Use of vitamin Ds to treat kidney disease
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Lucisano et al. New insights on the role of vitamin D in the progression of renal damage
Petkovich et al. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation
US20050148557A1 (en) Use of Vitamin Ds to treat kidney disease
JP5899165B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
FR2917975A1 (fr) Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
Wang et al. Topical calcitriol application promotes diabetic corneal wound healing and reinnervation through inhibiting NLRP3 inflammasome activation
Xiaowei et al. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria
Mende Application of direct renin inhibition to chronic kidney disease
KR101842295B1 (ko) 관절의 치료를 위한 주사가능한 약학 조성물
US20070093459A1 (en) Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
TW202339758A (zh) 藉由週期性遏制醛固酮合酶治療高血壓之方法
US20060171983A1 (en) Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
WO2025125409A1 (en) Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
Miyata et al. Renoprotective effects of direct renin inhibition in glomerulonephritis
MX2007001136A (es) Uso de vitamina s para tratar enfermedad renal.
US20050192255A1 (en) Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
E Gullo et al. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?
CN100589806C (zh) 类固醇衍生物在制备治疗血管紧张素ⅱ相关性疾病如心血管性和增生性疾病的药物中的应用
US20050074488A1 (en) Use of vitamin Ds to down regulate the renin-angiotensin-aldosterone system
Keogh et al. The antiatherogenic effects of calcium antagonists
WO2005011660A1 (en) Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
Mendes et al. The role of Paricalcitol in urinary albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease
WO2025222001A1 (en) Compositions and methods for treating chronic allograft rejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080707

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110224